Titre : Syndécane-3

Syndécane-3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Motor Vehicles
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syndécane-3 : Questions médicales les plus fréquentes", "headline": "Syndécane-3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syndécane-3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-30", "dateModified": "2025-04-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syndécane-3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndécanes", "url": "https://questionsmedicales.fr/mesh/D053667", "about": { "@type": "MedicalCondition", "name": "Syndécanes", "code": { "@type": "MedicalCode", "code": "D053667", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847" } } }, "about": { "@type": "MedicalCondition", "name": "Syndécane-3", "alternateName": "Syndecan-3", "code": { "@type": "MedicalCode", "code": "D053670", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Addolorata Pisconti", "url": "https://questionsmedicales.fr/author/Addolorata%20Pisconti", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, IIB, University of Liverpool, Liverpool, UK." } }, { "@type": "Person", "name": "Martin Götte", "url": "https://questionsmedicales.fr/author/Martin%20G%C3%B6tte", "affiliation": { "@type": "Organization", "name": "Department of Gynecology and Obstetrics, Münster University Hospital, Albert-Schweitzer-Campus 1, D11, 48149 Muenster, Germany." } }, { "@type": "Person", "name": "Ilona Kovalszky", "url": "https://questionsmedicales.fr/author/Ilona%20Kovalszky", "affiliation": { "@type": "Organization", "name": "Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary." } }, { "@type": "Person", "name": "Samantha Arokiasamy", "url": "https://questionsmedicales.fr/author/Samantha%20Arokiasamy", "affiliation": { "@type": "Organization", "name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom." } }, { "@type": "Person", "name": "James R Whiteford", "url": "https://questionsmedicales.fr/author/James%20R%20Whiteford", "affiliation": { "@type": "Organization", "name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Comparison of motor-vehicle involved e-scooter fatalities with other traffic fatalities.", "datePublished": "2022-10-28", "url": "https://questionsmedicales.fr/article/36868674", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jsr.2022.10.008" } }, { "@type": "ScholarlyArticle", "name": "Haboob Dust Storms and Motor Vehicle Collision-related Trauma in Phoenix, Arizona.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37527375", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5811/westjem.59381" } }, { "@type": "ScholarlyArticle", "name": "Electromagnetic Exposure Levels of Electric Vehicle Drive Motors to Passenger Wearing Cardiac Pacemakers.", "datePublished": "2024-07-06", "url": "https://questionsmedicales.fr/article/39001174", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/s24134395" } }, { "@type": "ScholarlyArticle", "name": "Blame attribution analysis of police motor vehicle collision reports involving child bicyclists.", "datePublished": "2023-06-09", "url": "https://questionsmedicales.fr/article/37295929", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/ip-2023-044884" } }, { "@type": "ScholarlyArticle", "name": "Drowsy driving and teen motor vehicle crashes: Impact of changing school start times.", "datePublished": "2022-06-02", "url": "https://questionsmedicales.fr/article/35652816", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jad.12053" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Glycoprotéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008562" }, { "@type": "ListItem", "position": 6, "name": "Syndécanes", "item": "https://questionsmedicales.fr/mesh/D053667" }, { "@type": "ListItem", "position": 7, "name": "Syndécane-3", "item": "https://questionsmedicales.fr/mesh/D053670" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syndécane-3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syndécane-3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syndécane-3", "description": "Comment diagnostiquer une anomalie du syndécane-3 ?\nQuels examens sont utilisés pour évaluer le syndécane-3 ?\nLe dosage sanguin peut-il aider au diagnostic ?\nQuels marqueurs sont associés au syndécane-3 ?\nLe diagnostic est-il difficile à établir ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Motor+Vehicles&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syndécane-3", "description": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?\nLe syndécane-3 est-il lié à des maladies spécifiques ?\nPeut-on observer des symptômes cutanés ?\nY a-t-il des symptômes systémiques associés ?\nLes symptômes varient-ils d'un patient à l'autre ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Motor+Vehicles&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syndécane-3", "description": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?\nY a-t-il des facteurs de risque connus ?\nDes dépistages réguliers sont-ils recommandés ?\nL'alimentation influence-t-elle le syndécane-3 ?\nLe stress a-t-il un impact sur le syndécane-3 ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Motor+Vehicles&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syndécane-3", "description": "Quels traitements ciblent le syndécane-3 ?\nLe traitement est-il efficace ?\nY a-t-il des effets secondaires des traitements ?\nDes traitements expérimentaux existent-ils ?\nLe suivi est-il nécessaire après traitement ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Motor+Vehicles&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syndécane-3", "description": "Quelles complications peuvent survenir avec le syndécane-3 ?\nLe syndécane-3 est-il lié à des complications cardiovasculaires ?\nDes complications neurologiques sont-elles possibles ?\nComment gérer les complications liées au syndécane-3 ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Motor+Vehicles&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syndécane-3", "description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il les risques ?\nLes infections jouent-elles un rôle ?\nY a-t-il un lien avec l'obésité ?\nLes facteurs environnementaux sont-ils significatifs ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Motor+Vehicles&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie du syndécane-3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques et des analyses de tissus pour évaluer l'expression du syndécane-3." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer le syndécane-3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des analyses immunohistochimiques peuvent être réalisées pour évaluer le syndécane-3." } }, { "@type": "Question", "name": "Le dosage sanguin peut-il aider au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de dosage sanguin standardisé pour le syndécane-3." } }, { "@type": "Question", "name": "Quels marqueurs sont associés au syndécane-3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs tumoraux et des cytokines peuvent être associés à l'expression du syndécane-3." } }, { "@type": "Question", "name": "Le diagnostic est-il difficile à établir ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diagnostic peut être complexe en raison de la variabilité de l'expression du syndécane-3." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des troubles de l'adhésion cellulaire et des anomalies tissulaires." } }, { "@type": "Question", "name": "Le syndécane-3 est-il lié à des maladies spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est impliqué dans des maladies comme le cancer et les maladies inflammatoires." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cutanés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent survenir en raison de l'implication du syndécane-3 dans la peau." } }, { "@type": "Question", "name": "Y a-t-il des symptômes systémiques associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes systémiques comme la fatigue et la douleur peuvent être observés dans certains cas." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'un patient à l'autre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier considérablement selon l'individu et la pathologie associée." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques associés." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque connus ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme l'inflammation chronique et des prédispositions génétiques sont identifiés." } }, { "@type": "Question", "name": "Des dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages peuvent être recommandés pour les personnes à risque élevé de maladies associées." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le syndécane-3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut influencer positivement l'expression du syndécane-3." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le syndécane-3 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut affecter l'expression du syndécane-3 et contribuer à des maladies." } }, { "@type": "Question", "name": "Quels traitements ciblent le syndécane-3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des anticorps monoclonaux peuvent être utilisés pour cibler le syndécane-3." } }, { "@type": "Question", "name": "Le traitement est-il efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité du traitement dépend de la pathologie et de l'expression du syndécane-3." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent entraîner des effets secondaires comme des réactions immunitaires." } }, { "@type": "Question", "name": "Des traitements expérimentaux existent-ils ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements expérimentaux sont en cours d'évaluation pour cibler le syndécane-3." } }, { "@type": "Question", "name": "Le suivi est-il nécessaire après traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour évaluer la réponse au traitement et ajuster si nécessaire." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le syndécane-3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des métastases tumorales et des troubles immunitaires peuvent survenir." } }, { "@type": "Question", "name": "Le syndécane-3 est-il lié à des complications cardiovasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études suggèrent un lien entre le syndécane-3 et des complications cardiovasculaires." } }, { "@type": "Question", "name": "Des complications neurologiques sont-elles possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines recherches indiquent que des complications neurologiques peuvent être associées." } }, { "@type": "Question", "name": "Comment gérer les complications liées au syndécane-3 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les antécédents familiaux et les maladies inflammatoires." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les risques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques." } }, { "@type": "Question", "name": "Les infections jouent-elles un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections chroniques peuvent augmenter le risque de dysfonction du syndécane-3." } }, { "@type": "Question", "name": "Y a-t-il un lien avec l'obésité ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité est un facteur de risque reconnu pour des dysfonctionnements associés au syndécane-3." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils significatifs ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des polluants environnementaux peut influencer l'expression du syndécane-3." } } ] } ] }

Sources (10000 au total)

Comparison of motor-vehicle involved e-scooter fatalities with other traffic fatalities.

Shared e-scooters are an emerging mode of transportation with many features that make their physical properties, behavior, and travel patterns unique. Safety concerns have been raised concerning their... Using media and police reports, a crash dataset was developed of rented dockless e-scooter fatalities in crashes involving motor vehicles that occurred in the United States in 2018-2019 (n = 17) and t... Compared to fatalities from other modes of transportation, e-scooter fatality victims are younger and more likely male. More e-scooter fatalities occur at night than any other mode, except pedestrians... E-scooter users share a mix of the same vulnerabilities as both pedestrians and cyclists. Although e-scooter fatalities are demographically most similar to motorcycle fatalities, crash circumstances s... E-scooter use must be understood by users and policymakers to be a distinct mode of transportation. This research highlights the similarities and differences between similar modes, like walking and cy...

Haboob Dust Storms and Motor Vehicle Collision-related Trauma in Phoenix, Arizona.

The Sonoran Desert region, encompassing most of southern Arizona, has an extreme climate that is famous for dust storms known as haboobs. These storms lead to decreased visibility and potentially haza... This study is a retrospective analysis of MVC-related trauma presentations to Phoenix, AZ, hospitals before and following haboob dust storms. These events were identified from 2009-2017 primarily usin... There were 31,133 MVC-related trauma encounters included from 2009-2017 and 111 haboob events meeting meteorological criteria during that period. There was a 17% decrease in MVC-related ED encounters ... Haboob dust storms in Phoenix, Arizona, are associated with a decrease in MVC-related injuries during the six-hour period following storm onset, likely indicating the success of public safety messagin...

Blame attribution analysis of police motor vehicle collision reports involving child bicyclists.

Injuries resulting from collisions between a bicyclist and driver are preventable and have high economic, personal and societal costs. Studying the language choices used by police officers to describe... A document analysis approach was used to analyse Alberta Transportation police collision reports from Calgary and Edmonton (2016-2017). Collision reports were categorised by the research team accordin... Of 171 police collision reports included, child bicyclists were perceived to be at fault in 78 reports (45.6%) and adult drivers were perceived at fault in 85 reports (49.7%). Child bicyclists were po... This work provides an opportunity to re-examine perceptions of factors related to motor vehicle and child bicyclist collisions with a view to prevention....

Drowsy driving and teen motor vehicle crashes: Impact of changing school start times.

Motor vehicle crashes (MVC) are the second leading cause of death for adolescents in the United States, with drowsy driving a major contributing factor. Early school start times have been identified a... Secondary school students (10th and 11th grade, 51.7% female, 67.8% White) in the United States completed annual surveys 1 year before and 2 years after implementation of later school start times (70-... With later start times, there was a significant drop in the percent of students who reported frequent drowsy driving (pre-change: 32.6%, post-change: 21.9%, follow-up: 22.8%). Weekday teen MVC rates w... Healthy school start times are important for adolescent health and safety, with study findings highlighting the downstream effects of increased sleep duration following a 70-min delay in secondary sch...

Ocular injuries associated with motor vehicle accidents: long term effects on quality of life.

To describe the prevalence and outcome of motor vehicle accidents-associated ocular injuries.... A survey of patients who presented to the emergency room at a level 1 trauma center with motor vehicle accidents-associated ocular injuries. A patient questionnaire and review of clinical notes were c... Of 274 motor vehicle accident victims with ocular injuries who presented to the emergency room, 40 (15%) responded to the survey. Over half of them were driving a vehicle, and most reported wearing a ... Our study sheds light on the details and extent of ocular involvement and the visual ability to perform daily activities following motor vehicle accidents....

Biopsychosocial sequelae and recovery trajectories from whiplash injury following a motor vehicle collision.

Five out of 10 injured in a motor vehicle collision (MVC) will develop persistent pain and disability. It is unclear if prolonged symptoms are related to peritraumatic pain/disability, psychological d... To test if widespread muscle fat infiltration (MFI) was (1) unique to those with poor recovery, (2) present in the peritraumatic stage, (3) related to known risk factors.... A cohort study, single-center academic hospital.... A total of 97 men and women (age 18-65) presenting to an urban academic emergency medicine department following MVC, but not requiring inpatient hospitalization.... Neck disability at 12-months.... Participants underwent magnetic resonance imaging (MRI) to quantify neck and lower extremity MFI, completed questionnaires on pain/disability and psychological distress (< 1-week, 2-weeks, 3-, and 12-... Significant differences for neck MFI were revealed, with the Recovered group having significantly lower neck MFI than the Mild and Moderate/Severe groups at all time points. The Mild group had signifi... Higher neck MFI and distress may represent a risk factor though it is unclear whether this is a pre-existing phenotype or result of the trauma.... ClinicalTrials.gov Identifier: NCT02157038....

Risk of motor vehicle collisions after methadone use: A systematic review and meta-analysis.

Methadone maintenance therapy is a leading treatment strategy for stabilizing and rehabilitating patients with opioid dependence; however, findings related to the risk of motor vehicle collisions afte... We completed a systematic review and meta-analysis of studies identified on six databases. Two reviewers independently screened the identified epidemiological studies, extracted data, and used the New... Among 1446 identified relevant studies, a total of 7 epidemiological studies enrolling 33226142 participants met the inclusion criteria. Overall, study participants with methadone use had a higher ris... The present review revealed that methadone use is significantly associated with a nearly doubled risk of motor vehicle collisions. Therefore, clinicians should exercise caution in implementing methado...

Psychiatric symptoms and pain in maxillofacial injury following motor vehicle accidents: A comparative study.

Post-traumatic stress disorders, depression, and pain are rarely discussed in the literature on maxillofacial injuries, and psychiatric symptoms and pain are not identified and managed in such patient... In this cross-sectional study, people injured in motor vehicle accidents from March to September 2015 who were referred to a medical educational center in the northern part of Iran for treatment follo... Maxillofacial injured patients had significant differences in terms of post-traumatic stress disorder (p = .006), depression (p = .001), pain (p = .001), and length of hospital stay (p = .002) than pa... Motor vehicle accident victims with maxillofacial injuries suffered significantly more from post-traumatic stress disorders and depression, pain and length of hospital stay than patients with other in...

Evaluation of mechanism of injury criteria for field triage of occupants involved in motor vehicle collisions.

The mechanism of injury (MOI) criteria assist in determining which patients are at high risk of severe injury and would benefit from direct transport to a trauma center. The goal of this study was to ... Data were obtained from NASS and Crash Investigation Sampling System (CISS) for 2000-2009 and 2010-2019. Cases missing injury severity were excluded, and all other missing data were imputed. The outco... There were 150,683 (weighted 73,423,189) cases identified for analysis. There was a small but statistically significant improvement in the AUROC of the MOI criteria in the later decade (2010-2019; AUR... The MOI criteria for MVCs in the current CDC guidelines still perform well even as vehicle design has changed. However, the sensitivity of these criteria for older adults is much lower than for younge...